


Synthesis and Reactivity of Novel Fluorinated Tricyclic Dynemicin A Mimic

Jung Hee Kim, Keon Sang Ryoo, Jong-Ha Choi, and Yong Pyo Hong*

Department of Chemistry, Andong National University, Andong 760-749, Korea

Received October 18, 1999


Dynemicin A (**1**) is a potent antitumor antibiotic isolated from fermentation broth *micromonospora chersina*.¹ The pronounced cytotoxic activity of this compound has been attributed to its ability to undergo Bergman cyclization to give a phenylene diradical which initiates DNA cleavage.² Cycloaromatization of **1** is triggered by epoxide opening induced by developing electron density at C9.³ In the previous papers, we reported the substituent effect for epoxide opening with simple model compounds.⁴ For instance, compound **2** with fluorine at C3 showed higher electron density at C1a position and faster epoxide opening than unsubstituted one under acidic conditions. This result suggested the possibility that the tricyclic compound with fluorine at C3 could be developed as a new enediyne anticancer drug. In this paper, we describe the synthesis and acid-induced Bergman cyclization of a new enediyne compound with fluorine at C3.




Scheme 1 and 2 summarize the construction of a new enediyne compound **14** related to dynemicin A according to a modified procedure of a typical preparation method.⁵ H₂O₂ oxidation and subsequent acetylation with acetic anhydride of 3-fluoro-7,8,9,10-tetrahydrophenanthridine (**3**)^{4a} gave acetate **4** (Scheme 1). This acetate was hydrolyzed to alcohol **5** and then, oxidized to ketone **6**. Continuously, introduction of acetylene moiety at the C6 and the N5 protection led to **7** via silylation and desilylation. The treatment of the enone **7** with *m*CPBA yielded the epoxy ketone **8** (Scheme 2). Coupling of compound **8** and vinyl chloride **9** using Pd(0)-Cu(I) catalysis afforded an enediyne product **10**.

Desilylation of **10** with AgNO₃-KCN produced compound **11**, which was cyclized to give the 10-membered enediyne adduct **12** through treatment with lithium diisopropylamide (LDA). Finally, the desired compound **14**⁶ was obtained by the treatment of **12** with thiocarbonyldiimidazole followed by subsequent reduction of the imidazolide **13** with tributyltinhydride (^tBu₃SnH) in the presence of a catalytic amount of 2,2'-azobis(isobutyronitrile) (AIBN).

Acid-induced epoxide opening and Bergman cyclization




Scheme 1. C6 and C10 functionalization of tricyclic compound. Reagents and conditions: (a) 2.0 equiv of H₂O₂, AcOH, 70 °C, 8h, 78%; (b) Ac₂O, 25 °C, 2 h, 90%; (c) K₂CO₃ (cat.), MeOH, 25 °C, 5 h, 78%; (d) 1.5 equiv of PCC, CH₂Cl₂, 0 °C, 3h, 87%; (e) 1.2 equiv of ^tBuMe₂SiOSO₂CF₃, 1.5 equiv of Et₃N, CH₂Cl₂, 25 °C, 3h, 94%; (f) 1.2 equiv of ethynylmagnesium bromide, 1.1 equiv of PhOCOCl, THF, -78 °C to 25 °C, 40 min and then, 10% HCl, 25 °C, 12h, 100%.



Scheme 2. Synthesis of a new dynemicin A model **14**. Reagents and conditions: (a) 1.2 equiv of *m*CPBA, aq. NaHCO₃/CH₂Cl₂, 25 °C, 30 min, 64%; (b) 1.6 equiv of **9**, 0.06 equiv of Pd(PPh₃)₄, 0.24 equiv of CuI, 2.0 equiv of *n*BuNH₂, benzene, 25 °C, 1 h, 80%; (c) 4.0 equiv of AgNO₃, 7.0 equiv of KCN, THF/EtOH/H₂O, 25 °C, 25 min, 86%; (d) 1.0 equiv of LDA, toluene, -78 °C, 10 min, 75%; (e) 3.0 equiv of thiocarbonyldiimidazole, 0.6 equiv of DMAP, CH₂Cl₂, 25 °C, 24 h, 56%; (f) 2.0 equiv of ^tBu₃SnH, AIBN (cat.), toluene, 80 °C, 1h, 83%.

for new model compound **14** was performed to probe the possibility as a new enediyne anticancer drug. (Scheme 3). Treatment of **14** with *p*-toluenesulfonic acid monohydrate (TsOH · H₂O) at 40 °C gave the aromatized product **15**⁷ via



Scheme 3. Acid-induced Bergman cyclization of new compound.

epoxide opening in a quantitative yield. Expectedly, the reaction time was 25 min which was much faster than that of unsubstituted compound under the same reaction conditions.⁸ This result suggests that the stimulated Bergman cyclization through fluorine substitution at C3 could lead to potential activation as a drug.

Our experimental result spurred for us to proceed further synthesis which would be applied on biological test. Presently, the transformation of N5 protection in **14** which is easily removed under basic conditions is undergoing.

Acknowledgment. This work was supported by the Basic Science Research Institute Program (1998-015-D00174).

References

- Konishi, M.; Ohkuma, H.; Matsumoto, K.; Tsuno, T.; Kamei, H.; Miyaki, T.; Oki, T.; Kawaguchi, H.; VanDuyne, G. D.; Clardy, J. *J. Antibiot.* **1989**, *42*, 1449.
- Jones, R. R.; Bergman, R. G. *J. Am. Chem. Soc.* **1973**, *6*, 25.
- (a) Sugiura, Y.; Shiraki, T.; Konishi, M.; Oki, T. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 3831. (b) Langley, D. R.; Doyle, T. W.; Beveridge, D. L. *J. Am. Chem. Soc.* **1991**, *113*, 4395.
- (a) Hong, Y. P.; Woo, L. *Bull. Korean Chem. Soc.* **1997**, *18*, 229. (b) Hong, Y. P.; Woo, L. *J. Korean Chem. Soc.* **1998**, *42*, 467.
- (a) Nicolaou, K. C.; Dai, W.-M.; Wendeborn, S. V.; *Angew. Chem. Int. Ed. Engl.* **1991**, *30*, 1032. (b) Nicolaou, K. C.; Dai, W.-M.; Hong, Y. P.; Tsay, S.-C.; Baldrige, K. K.; Siegel, J. S. *J. Am. Chem. Soc.* **1993**, *115*, 7844. (c) Ryu, H. H.; Hong, Y. P. *Bull. Korean Chem. Soc.* **1996**, *17*, 831.
- Spectroscopic data for compound **14**. IR (CHCl₃): ν_{\max} = 3070, 2970, 2880, 2200, 1720, 1465, 1380, 1200; ¹H NMR (300 MHz, DMSO-d₆): δ = 7.49 (dd, J = 8.9, 6.2 Hz, 1H, aromatic), 7.47-7.39 (m, 3H, aromatic), 7.31-7.19 (m, 3H, aromatic), 7.14 (td, J = 8.6, 3.9 Hz, 1H, aromatic), 6.05 (dd, J = 9.9, 1.4 Hz, 1H, olefinic), 5.93 (dd, J = 9.9, 1.6 Hz, 1H, olefinic), 5.57 (br s, 1H, CHN), 4.07 (br s, 1H, CH₂CH), 2.35 (dd, J = 15.5, 7.4 Hz, 1H, CH₂), 2.21-2.10 (m, 1H, CH₂), 1.89-1.72 (m, 3H, CH₂CH₂), 1.61-1.53 (m, 1H, CH₂); ¹³C NMR (75 MHz, DMSO-d₆): δ = 161.2 (¹J_{CF} = 242 Hz), 152.2, 150.5, 136.5, 129.4, 129.3, 125.9, 125.8, 124.9, 122.2, 121.6, 113.1, 112.3, 102.3, 93.4, 91.0, 89.0, 69.5, 60.2, 49.2, 28.6, 22.7, 22.1, 15.2.
- Spectroscopic data for compound **15**. IR (CHCl₃): ν_{\max} = 3460, 3080, 2940, 1710, 1500, 1380, 1200; ¹H NMR (500 MHz, DMSO-d₆): δ = 7.81 (d, J = 8.4 Hz, 1H, aromatic), 7.64 (d, J = 6.8 Hz, 1H, aromatic), 7.62 (d, J = 6.8 Hz, 1H, aromatic), 7.48-7.45 (m, 3H, aromatic), 7.31-7.27 (m, 2H, aromatic), 7.22 (t, J = 6.8 Hz, 1H, aromatic), 7.15 (t, J = 6.8 Hz, 1H, aromatic), 6.94 (d, J = 7.4 Hz, 1H, aromatic), 6.89 (td, J = 8.4, 2.6 Hz, 1H, aromatic), 5.65 (br s, 1H, CHN), 5.22 (br s, 1H, OH), 5.10 (br s, 1H, OH), 3.18 (br s, 1H, CH₂CH), 2.28-2.21 (m, 1H, CH₂CH₂), 2.12-2.06 (m, 1H, CH₂CH₂), 1.74-1.71 (m, 1H, CH₂CH₂), 1.36-1.31 (m, 1H, CH₂CH₂), 1.25-1.22 (m, 2H, CH₂CH₂); ¹³C NMR (125.8 MHz, DMSO-d₆): δ = 160.3 (¹J_{CF} = 240 Hz), 151.0, 144.5, 139.2, 135.7, 133.7, 133.0, 129.9, 129.3, 128.3, 128.0, 127.5, 127.2, 126.7, 125.5, 124.5, 121.8, 80.7, 64.8, 64.4, 51.7, 39.0, 26.5, 18.2.
- The reaction time for unsubstituted model compound was 80 minutes. See 5c for details.